talniflumate

Action and Spectrum

Actions and Spectrum 

talniflumate consists of more intense analgesic action than niflumic acid could be attributed to the higher plasma drug concentration during the early period.  

Given that talniflumate is less irritant to the gastrointestinal mucosa than niflumic acid, talniflumate appears to be superior to niflumic acid in terms of activity and side effects. 

Drug Interaction

Adverse Reaction

Frequency not defined  

None

Black Box Warning

Black Box Warning 

None

Contraindication / Caution

Contraindication/Caution: 

Contraindication: 

• talniflumate should not be used in individuals with a known hypersensitivity or allergy to the drug or any of its components.  

Caution: 

• Patients with liver impairment should use talniflumate with caution.  
• Use the drug with caution in individuals with history of gastrointestinal disorders. 

Pregnancy / Lactation

Pregnancy consideration: 

Pregnancy category: N/A 

Lactation: Excretion into human milk is unknown  

Pregnancy Categories:         

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women. 

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology  

talniflumate inhibits the core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase).  

In vivo and in vitro study of talniflumate reduces GCNT3 gene expression and mucin synthesis. Talniflumate is a potent CaCC (calcium-activated chloride channel) blocker. 

Pharmacodynamics 

talniflumate is metabolized to niflumic acid, which has several pharmacodynamic effects.  

It prevents mucin synthesis then, talniflumate inhibits prostaglandin synthesis by cyclooxygenases, which aids in the treatment of pain and inflammation. 

Pharmacokinetics 

Absorption   

talniflumate is absorbed from the gastrointestinal tract into the bloodstream.  

Distribution 

talniflumate is distributed throughout the body.  

Metabolism 

talniflumate undergoes metabolism in the liver. 

Elimination and excretion 

The elimination of talniflumate and its metabolites from the body occurs mainly through urine.  

Adminstartion

Administration 

talniflumate is available in the form of tablets and it is administered via orally. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: talniflumate 

Why do we use talniflumate? 

talniflumate is used in the management of rheumatoid arthritis (RA).  

talniflumate is used to relieve pain and inflammation associated with various musculoskeletal disorders.  

talniflumate is used in the management of cystic fibrosis.